Yin 2012.

Methods	Allocation: randomised. Blinding: researcher‐blinded. Duration: 72 hours.
Participants	Diagnosis: ICD‐10 diagnosis of schizophrenia. N = 60 Age: range 20‐54 years. Sex: 33 males, 27 females. History: acute agitation; length of Illness: 1‐ 23 years. Excluded: "taking ziprasidone 3 months before recruitment; taking other schizophrenia medications 12 hours before recruitment; taking long‐term schizophrenia medication 2 weeks before recruitment; additive to drugs 3 months before recruitment; ECG irregular (QTc > 500msec)". Setting: inpatients, China.
Interventions	1. Haloperidol: starting dose 5 mg/IM/day; maximum dose 20 mg. N = 30. 2. Ziprasidone: starting dose 10 mg/IM/day; maximum dose 40 mg. N = 30.
Outcomes	Mental state: BPRS total. Adverse effects. Adverse effects: movement ‐ SAS.
Notes	*It is not clear if this paper presents the results from one centre of the Fang 2012 multi‐centre trial. Attempted to contact author to clarify.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised ‐ method of randomisation is not reported.
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Researcher blinded to assignment.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No evidence of incomplete outcome data.
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting.
Other bias	Low risk	None obvious.